Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

BACKGROUND: Imatinib mesylate has been a breakthrough treatment for chronic myeloid leukemia. It has become the ideal tyrosine kinase inhibitor and the standard treatment for chronic-phase leukemia. Striking results have recently been reported, but intolerance to imatinib and noncompliance with trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezende, Vinicius Marcondes, Rivellis, Ariane, Novaes, Mafalda Megumi Yoshinaga, de Alencar Fisher Chamone, Dalton, Bendit, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739544/
https://www.ncbi.nlm.nih.gov/pubmed/23946646
http://dx.doi.org/10.2147/DDDT.S42902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739544/
https://www.ncbi.nlm.nih.gov/pubmed/23946646
http://dx.doi.org/10.2147/DDDT.S42902

Ejemplares similares